1 citations
,
May 2023 in “Journal of the American Academy of Dermatology” In this retrospective study, 75% of patients with alopecia areata responded well to an 8-week oral methylprednisolone tapering treatment, but 28.4% relapsed within an average of 5.5 months; young age and extensive alopecia predicted poorer responses, and low vitamin D was linked to relapse.
January 2025 in “The Journal of Dermatology” In this study at Tohoku University Hospital, 41% of severe alopecia areata patients achieved significant hair regrowth with baricitinib treatment over 9 months, with predictors of better outcomes including shorter disease duration, female sex, initial mild disease, certain alopecia types, and prior IVMP therapy.
22 citations
,
January 1992 in “PubMed” This preliminary study suggests that baseline central serotonin turnover, indicated by CSF 5-HIAA levels, may influence treatment response to serotonin re-uptake inhibitors in women with trichotillomania.
July 2025 in “Dermatology and Therapy” This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.